alexa Toxicological evaluation of malonaldehyde: a 12-month study of mice.
Microbiology

Microbiology

Journal of Antivirals & Antiretrovirals

Author(s): Bird RP, Draper HH, Valli VE

Abstract Share this page

Abstract The chronic toxicity of malonaldehyde (MA) was evaluated using Swiss female mice. Beginning at 10 wk of age, MA was administered in the drinking water for 12 mo to groups of 50 animals at levels of 0.1, 1, and 10 micrograms/g body wt.d with 100 controls. The highest dose was associated with increased mortality (28\% versus 12-14\%). MA had no effect on body weight, organ weight, hematological indices, or the incidence of lesions in 27 tissues examined. More liver lesions were observed in the three treatment groups than in the controls (p less than 0.05), and the histopathologic scores for severity of lesions were significantly increased in the groups that received the two higher levels of MA. The liver lesions included anisokaryosis, changes in cytoplasmic volume with architectural derangements, necrosis and neoplastic changes (nodular hyperplasia, hepatoma, and hemangioma). There was no significant increase in specific neoplasms in the treated groups, but the incidence of total neoplasms and neoplastic lesions was dose-dependent (4\%, 8\%, and 12\%, respectively) (p less than 0.01). There was only one neoplasm (a hemangioma) among the controls (1\%). Three animals (6\%) given the highest dose of MA developed stomach neoplasms. In terms of human dietary exposure to MA, the lowest level of MA used in this study is about 10 times the estimated average daily intake of MA by the Canadian population on a body weight basis. This article was published in J Toxicol Environ Health and referenced in Journal of Antivirals & Antiretrovirals

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords